Literature DB >> 24167019

Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: a synthesis of published evidence.

Kalliopi Tanou1, Elias Zintzaras, Athanasios G Kaditis.   

Abstract

Allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis (CF) is treated with corticosteroids. Since elevated IgE is a cardinal abnormality, anti-IgE has been used sporadically as adjuvant treatment. In eight case reports, 13 children with CF and ABPA received anti-IgE resulting in improved FEV1 , fewer respiratory symptoms and decreased corticosteroid use.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  A. fumigatus; ABPA; anti-IgE

Mesh：

Substances：

Year:  2013        PMID： 24167019     DOI： 10.1002/ppul.22937

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN： 1099-0496


  18 in total

Review 1.  Off-Label Uses of Omalizumab.

Authors:  David El-Qutob
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

Review 2.  Biological Modulators in Eosinophilic Diseases.

Authors:  Panida Sriaroon; Mark Ballow
Journal:  Clin Rev Allergy Immunol       Date:  2016-04       Impact factor: 8.667

3.  [Cystic fibrosis and associated complications].

Authors:  C Schwarz; D Staab
Journal:  Internist (Berl)       Date:  2015-03       Impact factor: 0.743

Review 4.  Aspergillus Species in Bronchiectasis: Challenges in the Cystic Fibrosis and Non-cystic Fibrosis Airways.

Authors:  Sanjay H Chotirmall; Maria Teresa Martin-Gomez
Journal:  Mycopathologia       Date:  2017-05-17       Impact factor: 2.574

Review 5.  Current and future treatment options for cystic fibrosis lung disease: latest evidence and clinical implications.

Authors:  Claire Edmondson; Jane C Davies
Journal:  Ther Adv Chronic Dis       Date:  2016-05-01       Impact factor: 5.091

6.  Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett
Journal:  Clin Infect Dis       Date:  2016-06-29       Impact factor: 9.079

Review 7.  Antibiotic management of lung infections in cystic fibrosis. II. Nontuberculous mycobacteria, anaerobic bacteria, and fungi.

Authors:  James F Chmiel; Timothy R Aksamit; Sanjay H Chotirmall; Elliott C Dasenbrook; J Stuart Elborn; John J LiPuma; Sarath C Ranganathan; Valerie J Waters; Felix A Ratjen
Journal:  Ann Am Thorac Soc       Date:  2014-10

Review 8.  Emerging Fungal Threats in Cystic Fibrosis.

Authors:  C Schwarz; P Eschenhagen; J P Bouchara
Journal:  Mycopathologia       Date:  2021-07-28       Impact factor: 2.574

Review 9.  Progress in Definition, Prevention and Treatment of Fungal Infections in Cystic Fibrosis.

Authors:  Carsten Schwarz; Dominik Hartl; Olaf Eickmeier; Andreas Hector; Christian Benden; Isabelle Durieu; Amparo Sole; Silvia Gartner; Carlos E Milla; Peter James Barry
Journal:  Mycopathologia       Date:  2017-07-31       Impact factor: 2.574

Review 10.  Omalizumab in children.

Authors:  Amelia Licari; Alessia Marseglia; Silvia Caimmi; Riccardo Castagnoli; Thomas Foiadelli; Salvatore Barberi; Gian Luigi Marseglia
Journal:  Paediatr Drugs       Date:  2014-12       Impact factor: 3.022
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.